Table of contents
The following summarized guidelines for the evaluation and management of pre-excitation syndrome are prepared by our editorial team based on guidelines from the European Society of Cardiology (ESC 2020), the American Heart Association (AHA/HRS/ACC 2016), and the Heart Rhythm Society (HRS/PACES 2012).
Electrocardiography: as per ESC 2020 guidelines, consider obtaining noninvasive evaluation of the conducting properties of the accessory pathway in asymptomatic patients with pre-excitation.
Electrophysiology study: as per ESC 2020 guidelines, conduct an electrophysiology study using isoprenaline to risk stratify asymptomatic patients with pre-excitation having high-risk occupations/hobbies, and those participating in competitive athletics.
Show 2 more
Catheter ablation: as per ESC 2020 guidelines, perform catheter ablation in asymptomatic patients if electrophysiology testing using isoprenaline identifies high-risk properties, such as:
shortest pre-excited RR interval during AF ≤ 250 ms
accessory pathway effective refractory period ≤ 250 ms
multiple accessory pathways
inducible accessory pathway-mediated tachycardia.
Show 4 more
Patients with pre-excited atrial fibrillation, pharmacologic management
Consider administering IV formulations of the following medications for acute management of hemodynamically stable patients with pre-excited AF:
Do not use IV amiodarone in patients with pre-excited AF.
More topics in this section
Patients with pre-excited AF (synchronized electrical cardioversion)
Patients with ADHD
5.Follow-up and surveillance
Observation: as per ESC 2020 guidelines, consider obtaining clinical follow-up in asymptomatic patients with pre-excitation and a low-risk accessory pathway at invasive risk stratification.